Prescription Drugs : Market Research Report

Prescription Drugs

Published by: Global Industry Analysts

Published: Jul. 1, 2009 - 1810 Pages

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Quantitative Techniques & Analytics
II. EXECUTIVE SUMMARY: 1.INDUSTRY OVERVIEW & OUTLOOK; Emerging Markets to Drive Growth; Biotech Bankruptcies Rife in the Current Economic Downturn; Outsourcing - A Mixed Bag; Generics - The Bright Spot; Table 3: Generics Share in Select Markets Worldwide - United States, Germany, UK, Spain, Japan, Italy,France, Finland, Denmark, The Netherlands, Norway,and Ireland (includes corresponding Graph/Chart); Patent Expiries of Major Drugs: 2009-2012; Operational Restructuring; Policy Issues Threaten Innovation; Opportunities Outside Drug Development; Down the Distribution Chain; 2.LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE; Leading Prescription Drugs Worldwide - Lipitor Leads the Way; Table 6: Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Othersin US$ Billion (includes corresponding Graph/Chart); 3.THERAPEUTIC DRUG CLASSES; Lack of Product Differentiation Mars Prospects; Biologics to Reign Supreme; Respiratory Drugs; Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion)(includes corresponding Graph/Chart); Leading Schizophrenia Drugs; Patent Expiries of Leading Anti-Psychotic Drugs; Proton Pump Inhibitors; Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond; Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015; Competitive Landscape in the Global Erythropoietin Market; New and Pipeline Products; Table 12: Leading Anti-arthritic Drugs Worldwide -Value Sales for Years 2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart); Disease Statistics; Table 13: Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart); Pipeline Drugs in Antiepileptics; Table 14: Leading Anti-diabetic Drug Sales Worldwide:Value Sales for Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise, Januivia andByetta (includes corresponding Graph/Chart); 4.MARKET DYNAMICS; Aggressive M&A Deals by Japanese Companies; Patent Expiries for 2008 and 2007; Table 15: New Drugs Approval from 2003-2008(includes corresponding Graph/Chart); Table 17: Development of New Molecular Entities(Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods1998-2002 & 2003-2007 (includes correspondingGraph/Chart); New Molecular Entities (NMEs) Approved by FDA in 2008; Research and Development; Aging Population Drives Demand; 5.PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW; Evolution Of The Global Pharmaceutical Industry; Drug Development Process - FDA Perspective; Phase I Clinical Trial; 6.SELECT THERAPEUTIC CLASSES; Anti-Ulcerants; Combination Drugs; Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs); Monoamine Oxidase Inhibitors (MAOIs); Seizure Disorder Drugs; Antihistamines; Calcium Channel Blockers; Cholesterol Reducers; 7.MARKETING AND PROMOTIONS; Table 22: Promotional Spending through ProfessionalDetailing by Major Pharma Companies (2006 and 2007)in US$ Million - Pfizer, GlaxoSmithKline, Merck,AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly,Johnson & Johnson, Schering-Plough and Wyeth(includes corresponding Graph/Chart); Table 24: E-Promotional Spending by Major PharmaCompanies (2006 and 2007) in US$ Million - Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi-Aventis (includes corresponding Graph/Chart); 8.RECENT INDUSTRY ACTIVITY; Sun Pharmaceutical Acquires Chattem; Teva Acquires Barr; Fresenius Acquires APP Pharmaceuticals; Sanofi Pasteur Acquires Acambis; Shionogi Acquires Sciele; GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines; AstraZeneca Enters into an Agreement with Par Pharmaceutical; GSK to Acquire Genelabs; EMD Signs Licensing and Collaboration Deal with Theratechnologies; Forest Partners with Phenomix for Developing Diabetic Drug; UCB and Pfizer Establish Cyclofluidic; MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology; Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline; Roche, GlycArt and Genentech Sign Collaboration Agreement; Eisai Plans NDA Submission for Insomnia Drug; Ablynx and Merck Serono Sign Nanobodies® Agreement; Noven Enters Supply and License Agreements with P&G Pharmaceuticals; Roche Sells Four Pharmaceutical Products to Meda AB; Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal with Merck; GSK and Harvard Stem Cell Institute Team Up for Drug Discovery; GlaxoSmithKline and Actelion Collaborate; Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets; European Commission Approves Kuvan® of Merck Serono; Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO; Mylan Takes Over Merck’s Outstanding Generics Operations; King Pharmaceuticals to License Third Opioid Analgesic Product; EUSA Pharma Acquires Cytogen Corporation; Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS; Pfizer Settles Patent Litigation for Lipitor with Ranbaxy; Janssen to Launch J&J Group’s New Drugs in Japan; Dr. Reddy’s Completes Acquisition of Jet Generici Srl; Endo Pharmaceuticals Obtains US Rights for Novartis’ Voltaren® Gel; Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal; Forest, Mylan Amend Bystolic Agreement; Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit; Dyax Signs Licensing and Development Agreements with Sanofi-aventis; Pfizer Japan Secures Production and Marketing Approval for Champix®; Eisai Takes Over MGI Pharma; Dr. Reddy’s Enters Settlement Agreement with Novartis for Exelon®; EMEA Approves Second Biogeneric EPO, Retacrit; GSK and Santaris Pharma Collaborate in RNA Antagonists Research; Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease Agents; GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell Research; Eisai and BioArctic Ink Licensing Deal for BAN2401; Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India; Schering-Plough Takes Over Organon BioSciences; Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy; EPFL and Merck Serono Enter into Agreement; Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals; GSK Enters into Collaboration with Tolerx for Development of Novel Therapies; BMS, ImClone, Merck Serono Sign Erbitux® Agreement; Wockhardt to Market Gnosis’ SAMe in India; Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings; AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation; AMRI Inaugurates New Research Unit in Hyderabad; Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical; EUSA Acquires Assets of Innocoll; Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease; HHS Places an Order with GSK for Bulk H5N1 Antigen; Targacept Forges Partnership with GSK; Santarus and Victory Pharma Enter Into Co-Promotion Agreement; SCI Collaborates with High Q Foundation for Research on Huntington’s Disease; Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal; GlaxoSmithKline Establishes R&D Center in China; Ranbaxy to Acquire Be-Tabs Pharmaceuticals; GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted Infections; Cytos Biotechnology Grants Novartis with Global License for NicQb; Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in India; Roche Partners with Transgene to Focus on Therapeutic Vaccine Program; Roche to Acquire BioVeris Corporation; Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for TroVax®; Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug; Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN®; Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in Korea and Taiwan; Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody Programs; Roche Grants Glaxo with Exclusive Licensing Rights to its ‘Orlistat’ Drug; Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global Launch; Amgen Inks Three-year Aranesp Supply Agreement with Fresenius; Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX®; GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in the Netherlands; Mylan Laboratories Acquires 51.5% in Matrix; Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals; Gilead Sciences Acquires Myogen; 9.FDA APPROVALS FOR 2009, 2008 AND 2007; 10.A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY; Centocor Receives FDA Approval for Simponi…; Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets; Sandoz Introduces Eplerenone Tablets; Sandoz Unveils Generic Variant of Imitrex® Injection; Mylan Introduces Nisoldipine ER Tablets in US; Eisai and Helsinn Healthcare Introduce ALOXI® Injection for Prevention of PONV; Sandoz Introduces Generic Form of Altace®; Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA; Sandoz Re-Launches Generic Form of Bactocill® Injection; Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage Strengths; Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets; Merck Receives Approval for Isentress® …; Eisai Launches New Dose Formulations of Aricept® Tablets in Japan; Ranbaxy Obtains Health Canada Approval for Ran®-Lisinopril Oral Tablets; Sandoz Expands Range of Generic Augmentin® Drugs; Sandoz Introduces Generic Form of Toprol Xl® 50Mg Extended Release Tablet; Chugai and Maruho Announce the Launch of Oxarol® Lotion; Dr. Reddy’s Launches UltravexTM; Ranbaxy Introduces Osovair in India; Barr Unveils Generic ‘PROSCAR®’ Tablets; SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for Treating Acne; Takeda Launches duetact™ Combination Drug in USA; 11.FOCUS ON SELECT GLOBAL PLAYERS; Amgen, Inc. (USA); AstraZeneca (UK); Bayer AG (Germany); Dr. Reddy's Laboratories Ltd. (India); Eli Lilly and Company (USA); Genentech, Inc. (USA); Johnson & Johnson, Inc. (USA); Merck Serono International S.A. (Switzerland); Novartis AG (Switzerland); Pfizer, Inc. (USA); Sanofi-Aventis SA (France); Takeda Pharmaceutical Company Limited (Japan); Watson Pharmaceuticals, Inc. (USA); Wyeth (USA); 12.GLOBAL MARKET PERSPECTIVE; Table 26: World Historic Review for Prescription Drugs Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart); Table 27: World 15-year Perspective for Prescription Drugs Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003,2009 & 2015 (includes corresponding Graph/Chart); Table 28: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class - Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$Billion for Years 2006 through 2015 (includescorresponding Graph/Chart); Table 29: World Historic Review for Prescription Drugs Market by Therapeutic Class - Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart); Table 30: World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class- Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)
III. MARKET: 1.THE UNITED STATES; Leading Prescription Drugs in the US; Table 32: US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart); Table 33: US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene & Combinations, Anti-Depressants, Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic ThyroidHormones, Calcium Blockers, Benzodiazepines,and Others (includes corresponding Graph/Chart); Leading Players; Table 35: US Pharmaceutical Market (2006-2008): Percentage Breakdown of Dispensed Prescriptions forTeva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others(includes corresponding Graph/Chart); Table 36: Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart); Increasing Share of Government in Prescription Drug Spending; Drug Price Regulations in the US; Table 38: Pharmaceutical Promotional Spending inthe US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions(in US$ Billion) (includes correspondingGraph/Chart); Table 39: Major Prescription Drugs’ Distribution Channels in the US by Dispensed Prescriptions(2006-2008): Percentage Share Breakdown forChain Stores, Independent Stores, Food Stores,Long-term Care, and Mail Order (includescorresponding Graph/Chart); Fewer Product Launches; The 2006 Revision of Package Insert Format; Prescription Drug Pricing in US; Role of Mail-Order Pharmacies in Cost Containment; Strategic Corporate Developments; Select Key Players; B. Market Analytics; Table 43: US Recent Past, Current & Future Analysisfor Prescription Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid Regulators, Proton PumpInhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo MonoclonalAntibodies, Erythropoietins, Others, MarketAnalyzed with Annual Sales in US$ Billionfor Years 2006 through 2015 (includescorresponding Graph/Chart); Table 44: US Historic Review for Prescription Pharmaceuticals by Therapeutic Class - Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, SeizureDisorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed withAnnual Sales in US$ Billion for Years 2001 through2005 (includes corresponding Graph/Chart); Table 45: US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class - Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart); 2.CANADA; Major Therapeutic Classes; Prescription Drugs Spending on the Rise; New Patented Drugs- Adding Costs but Little Value; Table 48: Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research,Basic Research and Other Research Areas(includes corresponding Graph/Chart); Strategic Corporate Developments; B. Market Analytics; 3.JAPAN; Competitive Landscape; Table 52: Leading Prescription Drugs in Japan(2006 and 2007): Value Sales in US$ Million forBlopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin(includes corresponding Graph/Chart); Product Launches; Strategic Corporate Developments; Select Key Players; B. Market Analytics; 4.EUROPE; Biogenerics Foray into Europe; Europe - The Research and Production Hub for Vaccines Worldwide; Pharmaceutical Industry Overview In Select Countries; Exports; Genetically Manufactured Drugs; Cost Containment Efforts; Italy; Product Launches; Strategic Corporate Developments; Select Key Players; B. Market Analytics; Table 58: European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart); 5.ASIA-PACIFIC; Number of FDA Approved Plants in India Vis-à-Vis Other Countries; India to Emerge as an Important Pharmaceutical Manufacturing Center; Table 59: Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women’sHealth, Central Nervous System, Dermatology,and Others (includes correspondingGraph/Chart); Chinese Pharma Industry Remains Immune to Global Crisis, for Now; Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare System; Traditional Medicines - Substantial Share; Underserved Markets Prompt Government to Foster Development; Antidepressant Drugs to Exhibit Robust Sales; Distribution; Malaysia; Australia; Government’s Industry Development Programs; Product Launches; Strategic Corporate Developments; Select Key Players; B. Market Analytics; 6.LATIN AMERICA; B. Market Analytics; 7.REST OF WORLD; B. Market Analytics

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Prescription Drugs

Table of Contents

Abstract